Journal Menu
► ▼ Journal Menu-
- CIMB Home
- Aims & Scope
- Editorial Board
- Reviewer Board
- Topical Advisory Panel
- Instructions for Authors
- Special Issues
- Topics
- Sections & Collections
- Article Processing Charge
- Indexing & Archiving
- Editor’s Choice Articles
- Most Cited & Viewed
- Journal Statistics
- Journal History
- Journal Awards
- Conferences
- Editorial Office
Journal Browser
► ▼ Journal Browser-
arrow_forward_ios
Forthcoming issue
arrow_forward_ios Current issue - Volumes not published by MDPI
- Vol. 42 (2021)
- Vol. 41 (2021)
- Vol. 40 (2021)
- Vol. 39 (2020)
- Vol. 38 (2020)
- Vol. 37 (2020)
- Vol. 36 (2020)
- Vol. 35 (2020)
- Vol. 34 (2019)
- Vol. 33 (2019)
- Vol. 32 (2019)
- Vol. 31 (2019)
- Vol. 30 (2019)
- Vol. 29 (2018)
- Vol. 28 (2018)
- Vol. 27 (2018)
- Vol. 26 (2018)
- Vol. 25 (2018)
- Vol. 24 (2017)
- Vol. 23 (2017)
- Vol. 22 (2017)
- Vol. 21 (2017)
- Vol. 20 (2016)
- Vol. 19 (2016)
- Vol. 18 (2016)
- Vol. 17 (2015)
- Vol. 16 (2014)
- Vol. 15 (2013)
- Vol. 14 (2012)
- Vol. 13 (2011)
- Vol. 12 (2010)
- Vol. 11 (2009)
- Vol. 10 (2008)
- Vol. 9 (2007)
- Vol. 8 (2006)
- Vol. 7 (2005)
- Vol. 6 (2004)
- Vol. 5 (2003)
- Vol. 4 (2002)
- Vol. 3 (2001)
- Vol. 2 (2000)
- Vol. 1 (1999)
Need Help?
Curr. Issues Mol. Biol., Volume 48, Issue 3 (March 2026) – 100 articles
Cover Story (view full-size image):
Despite advances in screening and therapy, lung cancer remains a major contributor to cancer mortality. One mechanism of resistance to treatment may be changes in the tumor microenvironment (TME). The TME comprises components that can restrain tumor growth or, conversely, support immune evasion, therapy resistance, and metastatic spread. In lung cancer, the baseline immune landscape of the airway, environmental exposures, and comorbid inflammatory lung disease together establish a tissue context that can bias the TME toward immune surveillance or chronic, tumor-promoting inflammation. The goal of this review is to serve as a concise synthesis of lung tumor microenvironment biology, integrating oncogenic signaling, immune modulation, and therapeutic strategies into a framework accessible to a broad audience. View this paper
- Issues are regarded as officially published after their release is announced to the table of contents alert mailing list.
- You may sign up for e-mail alerts to receive table of contents of newly released issues.
- PDF is the official format for papers published in both, html and pdf forms. To view the papers in pdf format, click on the "PDF Full-text" link, and use the free Adobe Reader to open them.
Previous Issue
Next Issue
Issue View Metrics
Multiple requests from the same IP address are counted as one view.